Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other disease areas, through a collaboration that could generate more than $1.5 billion for the Lexington, MA, biotech..

辉瑞将应用Triana Biomedicines的target first和proximity first发现平台，通过一项可能为马萨诸塞州列克星敦生物技术公司创造超过15亿美元的合作，为肿瘤学和其他几个疾病领域的未指定“多个”靶点发现分子胶降解剂。。

Privately held Triana focuses on building a molecular glue pipeline developed through its platform, which is designed to identify small molecules that induce protein:protein interactions between disease targets and a component of the cell’s ubiquitin-proteasome system (UPS), thus altering the fate or function of the disease target protein..

私人持有的Triana专注于通过其平台开发的分子胶管道，该平台旨在识别诱导疾病靶标与细胞泛素-蛋白酶体系统（UPS）组成部分之间蛋白质：蛋白质相互作用的小分子，从而改变疾病靶蛋白的命运或功能。。

Triana applies its protein:protein pairing engine to identify E3 ligases that are potential matches, then launches a comprehensive glue discovery campaign covering diverse chemical spaces to identify new molecular glues.

Triana应用其蛋白质：蛋白质配对引擎来鉴定潜在匹配的E3连接酶，然后启动涵盖不同化学空间的全面胶水发现活动，以鉴定新的分子胶水。

The resulting molecular glue degraders eliminate disease-causing proteins by promoting their interaction with the cell’s UPS—namely enhancing binding between a disease-causing protein and an E3 ligase enzyme. According to Triana, the small molecules can effectively promote the formation of a complex between two proteins even with low binding affinity of the molecular glue to either protein partner..

由此产生的分子胶降解剂通过促进它们与细胞UPS的相互作用来消除致病蛋白，即增强致病蛋白与E3连接酶之间的结合。据Triana称，即使分子胶与任一蛋白质伴侣的结合亲和力较低，小分子也可以有效促进两种蛋白质之间复合物的形成。。

Triana says it applies genomic, functional, and translational data to prioritize disease targets and candidate E3 ligases for molecular glue discovery, creating a short list from the universe of more than 600 E3 ligases. The company’s technologies are designed to identify preferred E3 ligases for a specific disease target, then discover small molecules that directly promote the interaction of the disease target:E3 ligase pair..

Triana说，它应用基因组，功能和翻译数据来优先考虑疾病靶标和候选E3连接酶，以发现分子胶，从而从600多种E3连接酶中创建了一个简短的列表。该公司的技术旨在确定特定疾病靶标的首选E3连接酶，然后发现直接促进疾病靶标相互作用的小分子：E3连接酶对。。

Under their strategic collaboration and licensing agreement, Pfizer has agreed to pay Triana $49 million upfront and potentially more than $1.5 billion in payments tied to achieving milestones, plus tiered royalties.

根据他们的战略合作和许可协议，辉瑞已同意向Triana支付4900万美元的预付款，以及可能超过15亿美元的与实现里程碑相关的付款，再加上分层版税。

“This collaboration with Triana Biomedicines on molecular glue discovery reflects our commitment to exploring cutting-edge technologies to drive the next wave of potential breakthroughs,” Jeff Settleman, PhD, CSO of Pfizer Oncology.

“与Triana Biomedicines在分子胶发现方面的合作反映了我们致力于探索尖端技术，以推动下一波潜在突破，”辉瑞肿瘤学CSO Jeff Settleman博士说。

Growing interest

日益增长的兴趣

Pfizer is the latest biopharma giant over the past couple of years to launch a collaboration focused on molecular glues, reflecting a growing interest in the space.

辉瑞（Pfizer）是过去几年来最新推出的一家专注于分子胶合作的生物制药巨头，反映出人们对该领域的兴趣日益浓厚。

“It has become clear lately that molecular glue type binding can be considered as a new modality option, specifically for otherwise poorly druggable protein targets,” Angela Zhou, PhD, manager of scientific analysis and insights with CAS, a Division of the American Chemical Society, and colleagues concluded in a 2023 paper reviewing developments in molecular glue development..

“最近很明显，分子胶型结合可以被认为是一种新的模式选择，特别是对于其他药物不良的蛋白质靶标，”美国化学学会CAS科学分析和见解经理Angela Zhou博士及其同事在2023年的一篇论文中总结道，该论文回顾了分子胶开发的发展。。

Takeda Pharma in May inked an up-to-$1.2 billion, plus royalties, partnership with Degron Therapeutics to develop molecular glue-based therapies for unspecified “multiple” indications in glue candidates in oncology, neuroscience, and inflammation, using Degron’s GlueXplorer® platform. Candidates discovered through Degron’s platform would be shifted to Takeda for further development and commercialization..

武田制药（Takeda Pharma）于5月与德隆治疗公司（Degron Therapeutics）签署了一项高达12亿美元的合作协议，外加版税，以开发基于分子胶的疗法，用于使用德隆的GlueXplorer®平台，在肿瘤学、神经科学和炎症的候选胶中开发未指明的“多种”适应症。通过德格隆平台发现的候选人将转移到武田进行进一步开发和商业化。。

Additional targets could be added if the companies exercise their option to expand their collaboration. Takeda also agreed at the time to make an equity investment of an unspecified amount in Degron, which will retain full ownership of its pipeline programs. Degron is based in San Diego and Shanghai, China..

如果公司行使扩大合作的选择权，则可以增加其他目标。武田当时还同意对德隆进行未指明金额的股权投资，德隆将保留其管道项目的全部所有权。Degron总部位于圣地亚哥和中国上海。。

Novo Nordisk launched an up-to-$1.46 billion partnership in February with San Diego-based Neomorph to discover, develop, and commercialize molecular glue degraders for unspecified targets in cardiometabolic and rare diseases, tapping into Novo Nordisk’s expertise in both therapeutic areas.

2月，诺和诺德与总部位于圣地亚哥的Neomorph建立了高达14.6亿美元的合作伙伴关系，以发现、开发和商业化分子胶降解剂，用于心脏代谢和罕见疾病的未指定目标，利用诺和诺德在这两个治疗领域的专业知识。

“This collaboration will enable the expansion of our platform into new therapeutic areas, complementing our ongoing efforts in oncology,” Phil Chamberlain, DPhil, co-founder, president, and CEO of Neomorph, stated at the time.

Neomorph联合创始人、总裁兼首席执行官Phil Chamberlain当时表示：“这种合作将使我们的平台扩展到新的治疗领域，补充我们在肿瘤学方面正在进行的努力。”。

And in September 2023, Genentech, a Member of the Roche Group, committed $47 million upfront, and potentially up-to-$2 billion-plus in milestone payments toward developing small molecule molecular glue therapies for “major disease areas” that include oncology and neurodegeneration, using Orionis’s Allo-Glue™ platform.

2023年9月，罗氏集团（Roche Group）成员基因泰克（Genentech）承诺预付4700万美元，并可能支付20多亿美元的里程碑式款项，用于开发针对“主要疾病领域”（包括肿瘤学和神经退行性疾病）的小分子分子胶疗法，使用Orionis的Allo-glue™平台。

Orionis agreed to oversee the discovery and optimization of molecular glues for Genentech’s designated targets, while Genentech is taking responsibility for later-stage preclinical, clinical development, regulatory filing, and commercialization..

Orionis同意监督Genentech指定目标的分子胶的发现和优化，而Genentech则负责后期的临床前，临床开发，监管备案和商业化。。

Bristol Myers Squibb and Merck & Co. have also initiated molecular glue alliances with smaller partners.

百时美施贵宝和默克公司也与较小的合作伙伴建立了分子胶联盟。

“This collaboration agreement signifies an important milestone in the evolution of Triana, as the company advances toward delivering on its product-focused strategy,” added Patrick Trojer, PhD, Triana’s president and CEO.

Triana总裁兼首席执行官Patrick Trojer博士补充道：“随着公司朝着以产品为中心的战略迈进，这项合作协议标志着Triana发展的一个重要里程碑。”。

GEN EdgeNewsBiomoleculesCellular, Molecular and Developmental BiologyMedicineMedicine, Diagnosis, and TherapeuticsMolecular biologyMolecular interactionMolecular medicineProteinsBristol Myers SquibbGenentechMerck & CoNovo NordiskPfizerRoche companyRoche PharmaTakeda Pharmaceutical Company

GEN EdgeNewsBiomoleculesCellular，Molecular and Developmental biologymedicine，Diagnosis，and therapesmolecular biologyMolecular interaction Molecular medicineProteinsBristol-Myers SquibbGenentechMerck&CoNovo NordiskPfizerRoche Companyyroche PharmaTakeda Pharmaceutical Company